Notably, surface FcμR levels were also significantly elevated in non-CLL B cells (CD5−/CD19+) and T cells (CD19−/CD5+), especially in better outcome CLL patients, when compared with the corresponding populations in healthy donors [45]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.